TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18703440
Drug: Combined pharmacologic
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pharmacologic and behavioral smoking cessation intervention (10-week group intervention + nicotine replacement therapy)
Study: 15989013
Drug: noliprel (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: noliprel (2 mg/0.625 mg)
Study: 15989013
Drug: caposide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: caposide (50 mg/25 mg)
Study: 7000589
Drug: Chromium-rich brewers'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium-rich brewers' yeast (9 g daily for 8 weeks)
Study: 31252146
Drug: Ketoconazole gel-flakes
Normalized name: ketoconazole Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole gel-flakes (50 mg/daily for three days)
Study: 31252146
Drug: Gynoconazol vaginal
Normalized name: lanoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynoconazol vaginal cream (80 mg terconazole/daily for three days)
Study: 25591635
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy including reflex action and tizanidine
Study: 25591635
Drug: Standard methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methods (reflex therapy of СЕЕР and local injections of a combination of local anesthetics with small doses of steroids)
Study: 22456862
Drug: Energy drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drink containing 80 mg of caffeine plus alcohol (0.046 and 0.087% breathalyser alcohol concentration)
Study: 20380913
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cannabis (19 mg delta‐9‐THC)
Study: 20380913
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cannabis
Study: 20380913
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high dose cannabis and alcohol
Study: 12711931
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g/kg, 10% w/v)
Study: 12711931
Drug: 4‐methylpyrazole (10‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐methylpyrazole (10‐15 mg/kg orally)
Study: 8590608
Drug: Ethanol 0.55
Normalized name: ethanol 0.55 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.55 g/kg
Study: 8739611
Drug: Ethanol 0.85
Normalized name: ethanol 0.85 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.85 g/kg
Study: 9377589
Drug: Phosphatidylcholine (PCh)
Normalized name: phosphatidylcholine, soybean
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine (PCh) 25 g
Study: 9377589
Drug: Phosphatidylcholine (PCh)
Normalized name: phosphatidylcholine, soybean
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine (PCh) 10 g
Study: 31124194
Drug: GSK2981710 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2981710 (30 g/day)
Study: 27383499
Drug: Dexmedetomidine (4μg/mL)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (4μg/mL) with 2mL load, 1.5ml background infusion, 0.5mL single dose, 20s locking time
Study: 27383499
Drug: Dexmedetomidine (4μg/mL)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (4μg/mL)
Study: 16877896
Drug: Risperidone (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4-6 mg/day)
Study: 17578722
Drug: E2 (Estrofem,
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (Estrofem, Novo Nordisk, Copenhagen, Denmark) 2 mg/d given orally over 3 months
Study: 15176764
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy (CRT) (n = 18)
Study: 15176764
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (occupational therapy activities) (n = 14)
Study: 15176764
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 19)
Study: 22743160
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment types
Study: 12490825
Drug: Venlafaxine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine therapy
Study: 12490825
Drug: Other antidepressants
Normalized name: Other antidepressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antidepressants (including tricyclic antidepressants and selective serotonin reuptake inhibitors)
Study: 11475716
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and Western Medicine (TCM‐WM)
Study: 11475716
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine alone (Control)
Study: 1842458
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low‐molecular dextran or low‐molecular hydroxyethyl starch and hyperbaric oxygenation
Study: 6889714
Drug: Cyclophosphamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide plus cisplatin (combination chemotherapy)
Study: 6889714
Drug: Cyclophosphamide (single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (single-agent chemotherapy)
Study: 28139349
Drug: Ozanezumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanezumab (15 mg/kg)
Study: 24918330
Drug: Subparaneural injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subparaneural injection of 0.3 mL/kg mepivacaine 10 mg/mL
Study: 24918330
Drug: Circumferential extraneural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumferential extraneural injection of 0.3 mL/kg mepivacaine 10 mg/mL
Study: 24918330
Drug: Unintentional intraepineural
Normalized name: HYALURONIC ACID 2.5 g INTRAEPIDERMAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unintentional intraepineural injection
Study: 15334437
Drug: Biofeedback-assisted cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback-assisted cognitive-behavioral treatment (BF/CBT)
Study: 11322865
Drug: Conventional drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs in different combinations
Study: 11322865
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment approaches for refractory cGvHD
Study: 9853887
Drug: Methotrexate treatment
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate treatment (1 mg/kg injected transvaginally or intramuscularly)
Study: 8011799
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 0.25, 0.5, and 1.0 mg
Study: 7143011
Drug: Cyproheptadine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (6 mg to 24 mg per day)
Study: 31328281
Drug: Family-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused cognitive behavioral treatment (F-CBT)
Study: 23173830
Drug: Enhanced treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment-as-usual (E-TAU)
Study: 28894075
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution (0.12% dilution)
Study: 19735563
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy exclusively with standardized protocols
Study: 19735563
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with Shoulder Dynasplint and standardized Physical Therapy
Study: 15209578
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1000 mg PO 1 hour before cath/PCI and 4 hours later
Study: 11755455
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 300 microg of CNP
Study: 9520616
Drug: Methimazole treatment
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole treatment for 11.2 ± 1.0 weeks
Study: 7975860
Drug: Plasma-derived vaccine
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived vaccine (Hevac B)
Study: 7975860
Drug: Recombinant HBsAg
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HBsAg vaccine (Engerix-B)
Study: 3132383
Drug: roxithromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (150 mg 2 X day)
Study: 3132383
Drug: cephradine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: cephradine (1.0 g 2 X day)
Study: 31230261
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg + Aspirin 100 mg
Study: 28463849
Drug: Febuxostat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (40 mg thrice weekly)
Study: 25416737
Drug: Mirror therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy-based action observation (AO) group
Study: 23353589
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia followed by intravenous morphine analgesia (Group A)
Study: 21533031
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination ART
Study: 16483745
Drug: Aripiprazole (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (initiated at 15 mg/d, adjusted between 10-30 mg/d)
Study: 16483745
Drug: Safety Control
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety Control (another antipsychotic medication, dosed according to prescribing guidelines)
Study: 9165611
Drug: Alarm plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm plus 40 micrograms desmopressin (Minirin, DDAVP) nasal spray
Study: 16140092
Drug: Alarm monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm monotherapy
Study: 27163250
Drug: Mobile upper
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile upper extremity rehabilitation program (MoU-Rehab) combined with conventional occupational therapy (OT)
Study: 27163250
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy (OT) alone
Study: 22815078
Drug: STAM‐Dem protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAM‐Dem protocol (2 weekly sessions of 45 minutes for 12 weeks)
Study: 20133918
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg IV tissue plasminogen activator within 3 hours of symptom onset
Study: 17853158
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg sublingual misoprostol 2 hours prior to the procedure
Study: 2208022
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
Study: 31227019
Drug: Misoprostol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (400 μg administered sublingually every 3 hours up to five doses within 24 hours)
Study: 28513179
Drug: Watermelon juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon juice enriched with l-Citrulline and pomegranate ellagitannins
Study: 24101149
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (OAC) discontinued after successful AF ablation; average 7.3 months follow-up off OAC.
Study: 2651016
Drug: Tizanidine (max.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (max. 20 mg/day)
Study: 2651016
Drug: Baclofen (max.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (max. 50 mg/day)
Study: 340132
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 g once daily for 3 days)
Study: 340132
Drug: Metronidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (2 g once daily for 3 days)
Study: 31109201
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (56 or 84 mg twice weekly) plus newly initiated antidepressant
Study: 31109201
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray plus antidepressant
Study: 21311345
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (CG)
Study: 19685935
Drug: Hypotonic PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic PEG (12 g once or twice daily or once every other day for 4 weeks)
Study: 19685935
Drug: Isotonic PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic PEG (12 g once or twice daily or once every other day for 4 weeks)
Study: 12020142
Drug: Alendronate, 10
Normalized name: Alendronate, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate, 10 mg/d
Study: 17074112
Drug: Tibolone, 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone, 1.25 mg/d
Study: 17074112
Drug: Calcium preparation
Normalized name: oyster shell calcium carbonate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium preparation only
Study: 9024732
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day supplemental water‐soluble dietary fiber (WSDF; a mixture of psyllium, pectin, guar gum, and locust bean gum)
Study: 8388352
Drug: Low-molecular-weight heparins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparins administered subcutaneously
Study: 29890086
Drug: Azithromycin (3×
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (3× weekly) with standardized tobramycin inhalation solution (TIS)
Study: 29890086
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with standardized tobramycin inhalation solution (TIS)
Study: 23419913
Drug: Multimodal physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal physical therapies
Study: 21170106
Drug: Alprostadil cream
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil cream 500 μg
Study: 21170106
Drug: Alprostadil cream
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil cream 700 μg
Study: 21170106
Drug: Alprostadil cream
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil cream 900 μg
Study: 11334057
Drug: PEG‐rHuMGDF at
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rHuMGDF at a dose of 5.0 microg/kg/day
Study: 8803380
Drug: Fentanyl citrate,
Normalized name: FentaNYL Citrate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl citrate, hydromorphone hydrochloride, methadone hydrochloride, and morphine sulfate solutions
Study: 6402914
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 to 60 mg/day orally)
Study: 23116022
Drug: Immunomodulator Lavomax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulator Lavomax and basic treatment: azithromycin (1.0 g once a week for 3 weeks), Celebrex, physiotherapy (low‐intensity laser radiation), prostate massage
Study: 14619336
Drug: Steroid resistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid resistant (SR) patients
Study: 14619336
Drug: Steroid sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid sensitive (SS) patients
Study: 8683967
Drug: 1.00 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.00 g/kg alcohol dose
Study: 21138709
Drug: 0.25 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g/kg alcohol dose
Study: 8683967
Drug: 0.50 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 g/kg alcohol dose
Study: 2003373
Drug: Acupuncture twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture twice a week for two months
Study: 6342554
Drug: 2.5% albumin‐lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% albumin‐lactated Ringer's solution
Study: 30852854
Drug: Intimacy-enhancing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intimacy-enhancing therapy (IET)
Study: 29600580
Drug: Acitretin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (0.4 mg/kg per day) plus nanocurcumin (3 g/day)
Study: 21913224
Drug: Safinamide 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safinamide 200 mg
Study: 21913224
Drug: Safinamide 100
Normalized name: safinamide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safinamide 100 mg
Study: 10861157
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intramuscular midazolam
Study: 3572102
Drug: Levamisole as
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole as an immuno-stimulator for 1 year along with chemotherapy
Study: 30502984
Drug: Subcutaneous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous tranexamic acid (TXA)
Study: 22520084
Drug: Vilanterol 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilanterol 6.25 mcg once-daily
Study: 22520084
Drug: Vilanterol 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilanterol 12.5 mcg once-daily
Study: 22520084
Drug: Vilanterol 25
Normalized name: FLUTIC 50/VILANTEROL 25MCG 30D ORAL INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilanterol 25 mcg once-daily
Study: 22520084
Drug: Vilanterol 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilanterol 6.25 mcg twice-daily
Study: 1916007
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day alpha‐glycerylphosphorylcholine (alpha‐GPC)
Study: 1916007
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day cytosine diphosphocholine (CDP)
Study: 30969960
Drug: Praziquantel from
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel from Nanjing Pharmaceutical Factory (NPF), China
Study: 23831177
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual combined with animal-assisted therapy (AAT) administered over 10 weekly sessions
Study: 20024643
Drug: BNP concentration
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP concentration > 50 pg/ml
Study: 20024643
Drug: BNP concentration
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP concentration median 11.3 pg/ml
Study: 17663620
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy for 2 months
Study: 31752976
Drug: Combination antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antimicrobial therapy
Study: 10189538
Drug: 5.07/10-g monofilament
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.07/10-g monofilament at five sites on the right foot
Study: 10189538
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sites 3 and 4 for monofilament testing
Study: 10189538
Drug: Monofilament with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monofilament with buckling force of 5 g and 15 g
Study: 7754764
Drug: alkylated immunoglobulin
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: alkylated immunoglobulin G intravenous preparation (IGIV) 200 mg/kg daily x 3 days + aspirin
Study: 7754764
Drug: alkylated immunoglobulin
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: alkylated immunoglobulin G intravenous preparation (IGIV) 400 mg/kg daily x 3 days + aspirin
Study: 7754764
Drug: native IGIV
Normalized name: IGIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: native IGIV 200 mg/kg daily x 5 days + aspirin
Study: 7754764
Drug: native IGIV
Normalized name: IGIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: native IGIV 400 mg/kg daily x 5 days + aspirin
Study: 8704439
Drug: Longevity-Antihypertensive-Mixture (LAM)
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longevity-Antihypertensive-Mixture (LAM)
Study: 2148508
Drug: Apocyhum Venetum
Normalized name: Apocynum cannabinum root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apocyhum Venetum L. Fluid (AVLF)
Study: 6945046
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg PGE2 for primigravidas
Study: 6945046
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg PGE2 for multigravidas
Study: 6945046
Drug: Conventional induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional induction by amniotomy and immediate oxytocin titration
Study: 30502372
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg monthly until complete resolution of SRF and IRF (intensive arm: SRF intolerant)
Study: 30502372
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg with treatment aimed at resolution of all IRF only (relaxed arm: SRF tolerant)
Study: 28530238
Drug: Duloxetine (AD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (AD treatment)
Study: 8929256
Drug: gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil 600 mg b.i.d.
Study: 9466127
Drug: gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil 600 mg b.i.d. (in patients with > or = 20% reduction in triglyceride levels)